Literature DB >> 30398639

Nonalcoholic Fatty Liver Disease.

Xiao Jing Wang1, Harmeet Malhi1.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease. Most cases are diagnosed incidentally in the primary care or hospital setting on the basis of elevated liver enzyme levels or hepatic steatosis on imaging. NAFLD encompasses a wide spectrum: The vast majority of patients have nonprogressive nonalcoholic fatty liver, and a few of those develop progressive liver injury, inflammation, and fibrosis, a condition termed nonalcoholic steatohepatitis. Cardiovascular disease is the leading cause of death in patients with nonalcoholic fatty liver disease. Persons with nonalcoholic steatohepatitis have increased liver-related mortality. In the absence of regulatory agency-approved drugs, lifestyle modification and weight loss remain the cornerstones of NAFLD therapy.

Entities:  

Mesh:

Year:  2018        PMID: 30398639     DOI: 10.7326/AITC201811060

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  28 in total

1.  Structurally-engineered fatty acid 1024 (SEFA-1024) improves diet-induced obesity, insulin resistance, and fatty liver disease.

Authors:  Jordon D Secor; Bennet S Cho; Lumeng J Yu; Amy Pan; Victoria H Ko; Duy T Dao; Michael Feigh; Lorenzo Anez-Bustillos; Gillian L Fell; David A Fraser; Kathleen M Gura; Mark Puder
Journal:  Lipids       Date:  2022-07-01       Impact factor: 1.646

2.  Association Between Triglyceride-Glucose Index and Risk of Metabolic Dysfunction-Associated Fatty Liver Disease: A Cohort Study.

Authors:  Ru Zhang; Qing Guan; Mengting Zhang; Yajie Ding; Zongzhe Tang; Hongliang Wang; Wei Zhang; Yue Chen; Rong Jiang; Yan Cui; Jie Wang
Journal:  Diabetes Metab Syndr Obes       Date:  2022-10-19       Impact factor: 3.249

3.  Predictive Factors and Time to Development of Hepatic Decompensation in Patients with Non-alcoholic Fatty Liver Disease.

Authors:  Heidi S Ahmed; Natalie Pedersen; Manju Bengaluru Jayanna; Patrick Ten Eyck; Antonio Sanchez; Arvind R Murali
Journal:  J Gen Intern Med       Date:  2020-03-10       Impact factor: 5.128

4.  Blueberry-derived exosomes-like nanoparticles ameliorate nonalcoholic fatty liver disease by attenuating mitochondrial oxidative stress.

Authors:  Wan-Jun Zhao; Yang-Ping Bian; Qiu-Hui Wang; Fei Yin; Li Yin; Yong-Lan Zhang; Jian-Hui Liu
Journal:  Acta Pharmacol Sin       Date:  2021-05-14       Impact factor: 6.150

5.  Association between fasting plasma glucose and nonalcoholic fatty liver disease in a nonobese Chinese population with normal blood lipid levels: a prospective cohort study.

Authors:  Yang Zou; Meng Yu; Guotai Sheng
Journal:  Lipids Health Dis       Date:  2020-06-20       Impact factor: 3.876

6.  Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) in Patients With Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis.

Authors:  Marieke de Vries; Jan Westerink; Karin H A H Kaasjager; Harold W de Valk
Journal:  J Clin Endocrinol Metab       Date:  2020-12-01       Impact factor: 5.958

7.  Association Between Dietary Fiber Intake and Non-alcoholic Fatty Liver Disease in Adults.

Authors:  Huimin Zhao; Aihua Yang; Lina Mao; Yaning Quan; Jiajia Cui; Yongye Sun
Journal:  Front Nutr       Date:  2020-11-19

8.  LDL/HDL cholesterol ratio is associated with new-onset NAFLD in Chinese non-obese people with normal lipids: a 5-year longitudinal cohort study.

Authors:  Yang Zou; Ling Zhong; Chong Hu; Mingchun Zhong; Nan Peng; Guotai Sheng
Journal:  Lipids Health Dis       Date:  2021-03-25       Impact factor: 3.876

9.  Healthy dietary patterns and metabolic dysfunction-associated fatty liver disease in less-developed ethnic minority regions: a large cross-sectional study.

Authors:  Xiaofen Xie; Bing Guo; Ting Chen; Baima Kangzhuo; Xing Zhao; Xiong Xiao; Jianzhong Yin; Ziyun Wang; Xiaoman Jiang; Jingzhong Li; Lu Long; Junmin Zhou; Ning Zhang; Yuan Zhang
Journal:  BMC Public Health       Date:  2022-01-17       Impact factor: 3.295

10.  Gallstone disease and nonalcoholic fatty liver disease in patients with type 2 diabetes: a cross-sectional study.

Authors:  Ye Lu; Lili Hu; Jing Song; Jing Wan; Haibing Chen; Jun Yin
Journal:  BMC Endocr Disord       Date:  2021-11-19       Impact factor: 2.763

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.